35th Annual New Treatments in Chronic Liver Disease

This conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. It will be comprehensive yet concise program for updating physicians on commonly encountered problems in the treatment of liver diseases.

Learning Objectives:

• Understand the details of the AASLD guidelines for treatment of HCV using DAA’s in IFN-free regimens
• Review current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions
• Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals
• Discuss therapies for HCV including NS5A, protease and polymerase inhibitors
• Update the skills and management required for transplant hepatology
• Apply current options of therapy for hepatocellular carcinoma to determine the best approach to patients
• Discuss future treatment paradigms for HCV direct-acting antiviral drug
• Describe the diagnosis and treatment of PBC and PSC
• Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder
• Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia
• Review the management of complications beta-blocker therapy in ESLD